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Aim of the study. Evaluation of long term results, the identification of the causes of the treatment failure and prog-
nostic factors in women with early invasive breast cancer after breast conserving treatment.
Material and methods. 1425 women with an early invasive breast cancer after breast conserving treatment under-
went postoperative radiotherapy in the Department of Radiotherapy of The Maria Skłodowska-Curie Memorial Cancer 
Center in Warsaw. Duration of the symptoms before diagnosis ranged from 0 (the tumor was found incidentally by 
mammography or ultrasound scan) to 84 months. In 1204 patients the size of the tumor did not exceed 2 cm. Most 
frequent localization was in external quadrants. 3 to 24 weeks after surgery all patients underwent breast irradiation 
with Co-60 or photons X 4–6 MeV in the dose of 42.5–50 Gy and next, 1405 of them received additionally 10–20 Gy to 
the site of the removed tumor, mostly with electrons of 9–15 MeV. In 489 the treatment was combined with chemo-
therapy and in 592 patients with hormone therapy.
Results. The tolerance of the treatment was good. In 1357 (95%) women the cosmetic effect of the treatment was 
evaluated as very good and good. 15-years overall survival (OS) rate was 85% and disease free survival (DFS) rate was 
79%. 15-years local recurrence rate risk was 6.9% and distant metastases occurred in 12.7%. Unfavourable prognos-
tic factors were: size of the tumor being more than 2 cm (T2), metastatic axillary lymph nodes (N 1–2), ductal type 
carcinoma and beginning of the treatment before the year 2006.
Conclusions. Breast conserving treatment is a safe and well tolerated method providing a high percentage of overall 
and disease free survival as well as good and very good cosmetic effects. Failure of the breast conserving treatment 
is relatively rare and is mostly due to the generalisation of the disease. The prognosis in this group of patients de-
pended on: the size of the primary tumor, presence of metastatic axillary lymph nodes, a ductal type of the cancer 
and timing of the beginning of treatment.
25 lat doświadczeń w leczeniu oszczędzającym u kobiet chorych na raka piersi we wczesnych 
stopniach zaawansowania
Cel pracy. Ocena odległych wyników, ustalenie przyczyn niepowodzeń i czynników rokowniczych u kobiet chorych 
na raka piersi we wczesnym stopniu zaawansowania. 
Materiał i metody. W latach 1985–2009 w Zakładzie Teleradioterapii Centrum Onkologii — Instytutu im. Marii 
Skłodowskiej-Curie w Warszawie napromieniano 1425 chorych na wczesnego inwazyjnego raka piersi po leczeniu 
oszczędzającym. Czas trwania objawów wahał się od 0 (guz wykryty przypadkowo w badaniu mammograficznym 
lub USG) do 84 miesięcy. U 1204 chorych wielkość guza nie przekraczała 2 cm. Nowotwór najczęściej umiejscawiał się 
w kwadrantach zewnętrznych. W okresie od 3 do 24 tygodni po zakończeniu leczenia chirurgicznego wszystkie chore 
zostały poddane napromienianiu na pierś wiązkami Co-60 lub Fot X 4–6 MeV w dawkach 42,5–50 Gy, a następnie 
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1405 z nich napromieniono dodatkowo na lożę po guzie w dawkach 10–20 Gy, przeważnie elektronami o energii 
9–15 MeV. U 489 chorych leczenie skojarzono z chemioterapią, a u 592 z hormonoterapią.
Wyniki. Tolerancja leczenia była dobra. U 1357 (95%) chorych stwierdzono bardzo dobry i dobry efekt kosmetyczny. 
Piętnastoletnie przeżycia całkowite (OS) wyniosły 85%, a przeżycia bezobjawowe (DFS) 79%. Piętnastoletnie ryzyko 
nawrotu miejscowego wyniosło 6,9%, a przerzutów odległych 12,7%. Wśród czynników mających niekorzystny wpływ 
na rokowanie należy wymienić: wielkość guza powyżej 2 cm (T2), obecność przerzutów w węzłach chłonnych pachy 
(N1–2), typ histologiczny raka przewodowego oraz czas rozpoczęcia leczenia przed 2006 r.
Wnioski. Leczenie oszczędzające jest bezpieczną i dobrze tolerowaną metodą postępowania, pozwalającą osiągnąć 
wysoki odsetek przeżyć całkowitych i bezobjawowych, jak i bardzo dobry i dobry efekt kosmetyczny. Niepowodzenia 
po leczeniu oszczędzającym są stosunkowo rzadkie i przeważnie związane z rozsiewem procesu nowotworowego. 
Rokowanie w analizowanej grupie chorych zależało od: wielkości guza pierwotnego, obecności przerzutów w węz-
łach chłonnych pachy, rozpoznania raka przewodowego w badaniu mikroskopowym i czasu rozpoczęcia leczenia.
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Introduction
It is now generally accepted that breast conserving 
surgery with subsequent irradiation (breast conserving 
treatment, BCT) is a standard procedure in women with 
early breast cancer. Many randomized controlled trials and 
meta-analyses published in 1990s and after 2000 showed 
that the results of BCT, when the patients were properly 
qualified, are identical with the results of the treatment of 
the patients who underwent mastectomy [1–6]. In all these 
trials a conventional method of irradiation of the whole 
breast in the daily dose of 1.8–2.0 Gy for five consecutive 
weekdays up to a total dose of 45–50.4 Gy was applied. Most 
patients, after whole breast irradiation, received an additio-
nal boost irradiation of the site of the removed tumor; which 
is a widely accepted approach in patients with a high risk of 
local recurrence (young age and a narrow margin of surgical 
excision). So far — optimal dose, the way of fractionation 
and the timing of additional irradiation of the site of the 
removed tumor are not unequivocally established. Updated 
results of the EORTC 22881 trial with a median follow up of 
10.8 years proved a significant reduction of local recurrence 
in patients who received additional irradiation of the site 
of the resected tumor with the dose of 16 Gy in 8 fractions 
compared to the group which was not irradiated (6.2% 
vs. 10.2% , p < 0.0001) [7]. Similar results were published 
by Romestaing et al. who applied additional irradiation of 
postoperative site in the dose of 10 Gy in 5 fractions resul-
ting in a reduction of local recurrence rate during 5 years 
follow up (3.6% vs. 4.5%, p = 0.044). However they observed 
increased number of post radiation complications such as 
teleangiectasiae of the 1st and 2nd degree (12.4% vs. 5.9%) 
[8]. Breast conserving treatment was started in our depart-
ment in 1985. Our initial experience presenting early results 
of the treatment and causes of failure of breast conserving 
procedure were published in 2000 and 2005 [9, 10]. The aim 
of the present study is the evaluation of the the long term 
results of the treatment including causes of failure and risk 
factors based upon our own 25 years of experience.
Material and methods
Between 1985 and 2009, 1425 women with invasive 
early breast cancer after breast conserving surgery were 
treated in the Department of Radiotherapy on the Maria 
Skłodowska-Curie Memorial Cancer Center in Warsaw. The 
mean age of the analysed group was 53.3 years; range: 
23–82 years. Duration of symptoms varied between 0 (the 
tumor was found incidentally in mammography or ultraso-
und scan) and 84 months. In 1204 cases the size of the tumor 
was 2 cm or less. Cancer was localized predominantly in 
external quadrants — 972 patients (68.2%). Characteristics 
of the analyzed group is displayed in Table I.
All 1425 women underwent breast conserving surgery 
— in 1325 it was tumorectomy, in 100 — quadrantectomy. In 
3 patients the primary tumor was not found — the removed 
lesions were diagnosed as metastatic lymph nodes. Lym-
phadenectomy or sentinel node biopsy was performed 
in 1415 patients. 10 patients had no surgical procedure 
on their axillary lymph nodes due to being over 75 years 
old or because of the size of the primary tumor was less 
than 0.5 cm (T1a). Predominant microscopic finding was 
ductal carcinoma (771 patients). Lobular carcinoma was 
found in 196 patients. Metastatic axillary lymph nodes were 
found in 304 patients (21.3%). 3 to 24 weeks after surgery 
all patients underwent radiotherapy of the whole breast. 
Initially we used the technique of two tangential 2D fields 
with use of Co-60 or photons X 4–6 MeV in the daily dose 
of 2 Gy up to the total dose of 50 Gy in 25 fractions. Since 
2004, in order to reduce the risk of relapse, especially on 
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the border of irradiated fields, we have used conformal 
3D radiotherapy in the same doses. In 2006, in order to 
reduce the duration of the treatment we have increased 
the fraction dose to 2.5 Gy and reduced the total dose to 
42.5 Gy (17 fractions). 1405 patients received additionally 
boost of 10–20 Gy to the site of the removed tumor, mostly 
with electrons at 9–15 MeV. 114 women were additionally 
irradiated because of metastatic axillary lymph nodes. If the 
patient was qualified for chemotherapy, especially with an-
thracyclines, radiotherapy was performed after completion 
of chemotherapy. In 489 patients radiotherapy was combi-
ned with chemotherapy — CMF or anthracyclines — due 
to unfavourable prognostic factors and in 592 patients with 
hormonal treatment due to positive estrogen and/or proge-
sterone receptors. Most often chemotherapy or hormonal 
treatment was used in patients treated since 2005. Che-
motherapy was applied in 167 and hormonal treatment in 
182 patients out of 380 treated between 2006–2009. Only 
31 women did not receive any form of systemic therapy. 
Methods of the treatment are displayed in Table II.
Statistical methods
Efficacy of the treatment was evaluated by overall su-
rvival (OS) from surgery until death — irrespective of the 
cause and by disease free survival (DFS) — from surgery till 
relapse: locoregional, distant metastasis or cancer unrelated 
death. The Kaplan-Meier method was used for evaluation of 
survival [11]. Cox proportional hazard models were used to 
evaluate the influence of selected factors on the risk of death 
and risk of failure [12]. Following variables were included in 
the model : localization of the tumor (right or the left side), 
age of the patient, year of treatment, size of tumor, presence 
or absence of metastatic lymph nodes, histological type of 
the tumor, histological malignancy G, duration of symptoms 
and hormonal status. Definition of included variables is 
displayed in Table I. Final models have been obtained by 
a backward selection procedure for inclusion and exclusion 
conditions: p = 0.05 and p = 0.1 respectively. Proportional 
hazards assumption was verified by graphical method. As 
a measure of local efficacy the cumulative incidence func-
tion (CIF) for the loco-regional recurrences has been applied. 
For the CIF estimation, competing risks methodology was 
used with local recurrence as the event and distant me-
tastasis or cancer unrelated death as the competing risks 
[13].  The 0.05 value was adopted as the general statistical 
significance level. To evaluate the cosmetic effect we used 
10-point and 4-point scale developed and introduced in 
1979 by Harris [14].
Results
In 85 (6%) of patients we had to suspend the treatment 
for more than 7 days because of an irradiation reaction of the 
2nd degree according to RTOG or leucopenia, especially in 
Table I. Descriptive statistics of variables defined for analysis
Name of the variable Category N = 1.425 %
Breast side left 720 50.4
right 705 49.6
Age (years) < 47 342 24.0
47–51 351 24.6
52–65 360 25.3
> 65 372 26.1
Start-of 
Therapy (year)
< 2000
2000–2002
311
352
21.8
24.7
2003–2005 382 26.8
≥ 2006 380 26.7
Symptoms duration
(month)
< 1
(1, 2)
836
244
58.7
17.1
(2, 4) 180 12.6
≥ 4 165 11.6
Location outer quadrants 972 68.2
inner quadrants 162 11.5
central portion 129 9.8
borderline 157 11.1
between
quadrants
no data 5
T-stage T1 1,204 84.5
T2 215 15.5
no data 6
N-stage N- 1,111 88.7
N+ 304 21.3
no data 10
Histological
malignancy G
G1
G2
268
541
18.8
37.9
G3 225 15.8
no data 391 27.5
Histology type ca ductale 771 54.1
ca lobulare 196 13.8
mixed + other 6 + 452 32.1
Menopausal status premenopause 515 36.2
postmenopause 907 63.8
no data 3
ER receptors ER positive 638 44.8
ER negative 157 11.0
unknown 630 44.2
PGR receptors PGR positive 571 40.0
PGR negative 221 15.6
unknown 633 44.4
HER2 receptors HER2 positive 20 1.4
HER2 negative 50 3.5
unknown 1.355 95.1
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cases with combined chemotherapy. In 1357 (95%) patients 
cosmetic effect was estimated as very good or good.
Fifteen-years overall survival (OS) was 85% and disease 
free survival (DFS) was 79% (Table III). OS and DFS curves 
for the whole group are shown in Fig. 1 and Fig. 2. Cumu-
lated incidence function is displayed in Fig. 3. Estimated 
values of respective functions with 95% confidence interval 
for 5, 10 and 15 years follow-up are displayed in Table III. 
Fifteen-years risk of loco-regional recurrence was 6.9%, of 
distant metastasis — 12.7% and of death unrelated to cancer 
— 1.9%. Parameters of Cox models are displayed in Table IV. 
Statistically significant influence on the death risk was stated 
for the year of beginning the therapy, size of the tumor — T 
and lymph nodes status — N. The death risk for women who 
started the treatment in 2006 or later constitutes 31% of the 
Table II. Treatment methods
Metods Category No. of patients %  
Surgery lumpectomy 1,325 93.0
quadrantectomy 100 7.0
regional lymphadenectomy 1,362 95.6
sentinel node biopsy (SNB) 53 3.7
without lymph node assessment 10 0.7
Radiotherapy the whole breast: yes 1,425 100.0
Co60, photons X 4–6 MeV no 0 0.0
local lymph nodes 114 8.0
boost: e 9–15 MeV, yes 1,405 98.6
Co60, photons X 4–6 MeV, Ir192 no 20 1.4
Chemotherapy yes 489 34.3
no 936 65.7
CMF 454 31.9
anthracyclines (AC, FAC, FEC) 35 2.5
herceptin 3 0.2
Hormonotherapy yes 592 41.5
no 833 58.5
A — doxorubicin, C — cyclophosphamine, E — epirubicin, F — fluorouracil, M — methotrexate
Table III. Overall and disease free survival probability and cumulative incidence function  for failures with 95%-confidence intervals for 5, 10 and 15 years 
of follow-up
5 years 10 years 15 years
Overall survival (OS) 0.96 (0.95; 0.97) 0.91 (0.89; 0.93) 0.85 (0.81; 0.89)
Disease free survival (DFS) 0.93 (0.92; 0.94) 0.84 (0.82; 0.87) 0.79 (0.75; 0.82)
Cumulative incidence function (CIF)
loco-regional recurrence .0114 (.0057; .0172) .0406 (.0262; .0551) .0685 (.0431; .0939)
distant metastasis .0537 (.0415; .0658) .0950 (.0767; .1134) .1271 (.0976; .1566)
cancer unrelated death .0037 (.0005; .0069) .0146 (.0062; .0230) .0191 (.0070; .0312)
Figure 1. Overall survival (OS) for the whole group
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death risk of the patients treated earlier (p = 0.012). Death 
risk for women with T2 tumors was 2 times higher than for 
women with T1 tumors (p = 0.002). Similarly, the death risk 
for patients with metastatic lymph nodes — N1–2 is twice 
as high for women without metastases — N0 (p = 0.004). 
Also these parameters, as well as the histological type of tumor, 
have a statistically significant impact on the risk of failure. Patients 
who started the treatment in 2006 or later have 42% of the recur-
rence or death risk of those patients treated earlier (p = 0.005). 
Recurrence or death risk for women with T2 tumors is 2 times 
higher compared to those women with T1 tumors. Similarly, 
risk of failure is more than twice as high for women with 
N1–2 tumors compared to women with N0 tumors (p < 0.001). 
The failure risk is 1,5 times higher for women with ductal carci-
noma than for women with other types of cancer (p = 0.018). 
Kaplan-Meier’s curves dependant on prognostic factors are 
displayed in Figs. 4–10. We found no statistically significant 
influence on prognosis by age, hormonal status, duration of 
symptoms and degree of histological malignancy G.
Discussion
The present approach to breast conserving treatment 
in women with early invasive breast cancer should achieve 
following goals:
 — to give a maximal chance for a curative result,
 — to minimalize the risk of local recurrence and distant 
metastases,
Table IV. Parameters of final Cox’s models
B BS p Relative Risk 95%-confidence interval
The Cox’s model for function of risk of death 
Therapy year (≥ 2006/< 2006) –1.184 .472 .012 .306 .121 .771
T-stage (T2/T1) .722 .235 .002 2.058 1.298 3.263
N-stage (N1/N0) .709 .243 .004 2.033 1.262 3.273
The Cox’s model for function of risk of failure 
Therapy year (≥ 2006/< 2006) –.879 .311 .005 .415 .226 .764
T-stage (T2/T1) .758 .183 < .001 2.135 1.492 3.054
N-stage (N1/N0) .708 .190 < .001 2.030 1.400 2.943
Histology type (ca ductale/other) .385 .163 .018 1.469 1.068 2.022
Figure 2. Disease free survival (DFS) for the whole group
Figure 3. Cumulative incidence function (CIF) for the whole group
Figure 4. Overall survival for T-stage groups
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Figure 10. Disease free survival for ca ductale group versus different 
histopathological diagnosis
Figure 5. Overall survival for N-stage groups
Figure 6. Overall survival for patients treated before and in or after 
2006 year
Figure 7. Disease free survival for patients treated before and in or 
after 2006 year
Figure 8. Disease free survival for T-stage groups
Figure 9. Disease free survival for N-stage groups
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 — to achieve a good cosmetic effect,
 — to obtain optimal data about type, malignancy and 
staging of the tumor in order to choose proper ad-
juvant treatment. Breast conserving surgery with 
subsequent radiotherapy meets all these require-
ments.
It is now generally accepted that breast conserving tre-
atment can be recommended for more than 50% of women 
with early invasive breast cancer. Analysis of randomized stu-
dies comparing breast conserving therapy with mastectomy 
proved that both approaches are equal with respect to ove-
rall survival, however local recurrence occurs more frequently 
in women after breast conserving treatment — it appears in 
10–20% of patients within 10 years after completion of their 
therapy [15]. The risk of local recurrence is highest during 
the first 5 years and ranges from 5 to 10% [16]. The highest 
percentage of recurrences — 23.3% within 25 years was 
stated in the NCI trial published in 2012 [17]. There are the 
following risk factors of local recurrence: the extent of the 
surgical excision (it is an important factor when evaluating 
the margins in a pathological examination), the presence 
of extensive intraductal component (EIC) adjacent to the 
primary tumor, emboli in the blood and lymphatic vessels 
surrounding the tumor, the mode and area of the irradiation, 
the necessity of introducing systemic therapy and the young 
age of the patients. The most important prognostic factor 
from a surgical point of view is the extent of excised normal 
tissue surrounding the primary lesion. If either the quadran-
tectomy or tumorectomy with a margin of healthy tissue of 
1.5–2 cm are performed, the risk of local recurrence does 
not exceed 2% within the first 5 years [18, 19]. Veronesi and 
Fisher compared and published results of a 20-year follow-
-up of patients with early invasive breast cancer after breast 
conserving treatment and mastectomy. Results from both 
authors were in fact the same and the risk of local recurrence 
was 8.8% and 14.3% respectively [3, 4]. In Arriagada’s trial, 
local recurrence was observed in 9% of the patients within 
a 15 year follow-up [1]. However, if the margin of healthy tis-
sue is narrow or not present at all, the risk of local recurrence 
is 10–20%. Diagnosis of local recurrence can be difficult as 
the neoplasmatic infiltration is often masked by fibrous post-
-radiation lesions. High doses applied during radiotherapy 
reduces the risk of local recurrence but simultaneously makes 
early diagnosis more difficult and can cause fatal delays re-
sulting in unresectability of the reoccurrent tumor. In 1/3 of 
the patients local recurrence is diagnosed by mammography, 
in a 1/3 by clinical examination and in a 1/3 by both clinical 
examination and mammography. Local recurrence is usually 
localized in the same place or near the primary tumor. If it 
is localized in a different quadrant of the breast than the 
primary tumor, it should not be classified as recurrence but 
rather as another primary cancer [20]. Veronesi et al. found 
local recurrence in 119 cases out of 2233 women with early 
invasive breast cancer. In 50% it was localized at the site of 
the removed primary tumor or adjacent to it; in the other 
50% it was localized in a different quadrant of the breast [21]. 
Fowble and Kurtz published different data — they found 
local recurrence mainly at the site of the removed primary 
tumor — in 65% and 79% respectively [20, 22].
In our material the risk of recurrence was 6.9% and in 
most cases it was localized at the site of the removed pri-
mary tumor (80%). Isolated local recurrent tumors can be 
effectively managed by radical mastectomy. In such cases 
survival for 5-years is between 50% and 84% [20, 23]. Re-
cently, there is a growing interest in biological factors and 
their influence on clinical course of breast cancer. Voogd 
et al. have presented results of a controlled trial evaluating 
the influence of histological factors on increased risk of 
recurrence after breast conserving treatment. They found 
a significantly increased risk of recurrence in cases with 
extensive intraductal component (EIC) or with emboli in 
blood and lymphatic vessels surrounding the tumor [24]. 
Similar results were obtained by Veronesi who stated that 
there was a double increase in the risk of local recurrence 
in cases with extensive intraductal component (EIC) [21]. 
In our institution all the patients in whom we found EIC on 
pathologic examination underwent radical mastectomy. 
The role of the emboli in blood and lymphatic vessels in 
prognosis of the outcome was not evaluated in our study 
due to insufficient information in our data base. Another 
factor with a potential influence on prognosis is the degree 
of histological malignancy (G). The patients with low G va-
lue (1-2) had significantly better prognosis (72% of 5-year 
survival) than the patients with high G value (40% of 5-year 
survival) [22]. In our material, however, this factor had no 
prognostic value. According to some authors the young age 
of the patient (less than 40 years) can have unfavourable 
prognostic value. Presumably this can be caused by the pre-
sence of less mature forms of the cancer and its multifocal 
character [25, 26]. In our study the age of the patients did 
not influence the prognosis.
The size of the tumor in our study played an important 
role as a prognostic factor. The patients with T2 tumor had 
a 2 times higher death risk and even higher risk of loco-re-
gional recurrence. Our data are similar to those published 
by Aristei et al. who analysed a group of 575 patients and 
found an increased risk of distant metastases in patients 
with T2 tumors [27]. One of most important prognostic 
factors with a direct influence on survival was the presence 
of metastatic lymph nodes. In our material we observed 
a 2 times higher risk of recurrence and death in patients with 
metastatic lymph nodes — N1–2 compared to the patients 
without metastases — N0. This data corresponds with data 
from other authors [4, 27, 28]. The ductal type of breast 
carcinoma also appeared to be an unfavourable progno-
stic factor and was probably caused by a high percentage 
204
of the special form of breast cancer which generally have 
a better prognosis. Better prognosis for patients treated 
after the year 2006 can be explained by an increased use 
of systemic treatment despite potentially better prognostic 
factors. Radiotherapy is an important element of the treat-
ment irrespective of the kind of surgical procedure. Many 
randomized trials published during last 15 years proved that 
patients who received radiotherapy have a 2–5 times lower 
risk of local recurrence than patients who were treated by 
surgery only, although direct influence of radiotherapy on 
overall survival has not been unequivocally proven [29–32]. 
However, meta-analysis of 17 randomized trials published in 
2011 by the Early Breast Cancer Trialists Collaborative Group 
(EBCTCG) proved that reduction of local reoccurrences due 
to postoperative irradiation also resulted in improvement 
of overall survival [33]. In our material all patients received 
irradiation of the whole breast — only 20 patients did not 
receive radiotherapy of the site of the removed tumor be-
cause of their age or the size of the primary tumor being 
less than 5 mm (T1a).
Conclusions
1. Breast conserving treatment in patients with early inva-
sive cancer is a safe and well tolerated procedure and 
enables achievement of a high percentage of overall 
and disease free survival (87% and 79% during 15-years 
follow-up, respectively).
2. Failures after breast conserving treatment are rare. Fif-
teen-years risk of local recurrence was 6.9% and of di-
stant metastases — 12.7%.
3. The treatment should be carefully considered in patients 
with unfavourable prognostic factors like size of the 
tumor being more than 2 cm (T2), metastatic lymph no-
des (N1–2), ductal type of carcinoma and the treatment 
being performed before 2006.
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